Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(3):182-184; doi:10.1093/jnci/95.3.182
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 3, 182-184, February 5, 2003
© 2003 Oxford University Press

NEWS

Trials Examine Intraepithelial Neoplasia as a Marker for Cancer

Tom Reynolds

The first 150 words of the full text of this article appear below.

For cancer chemoprevention, the definitive question—whether an agent reduces the risk of invasive cancer—typically takes many years, thousands of phase III trial participants, and millions of dollars to answer.

In search of quicker, preliminary answers, clinical prevention researchers are increasingly focusing their efforts on intraepithelial neoplasia (IEN), a group of cellular and genetic abnormalities that have been shown to be associated with invasive cancer at nearly every solid tumor site.

The initial report of the American Association for Cancer Research IEN Task Force, published in the February 2002 Clinical Cancer Research, offers, for each major cancer site, evidence of the links between IEN and invasive cancer and suggestions for the design of prevention trials.

The task force described several circumstances where effective chemoprevention agents could be beneficial, such as the prevention or treatment of IEN in patients with hereditary conditions such as familial adenomatous polyposis (FAP), which is a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?